跳转到内容

兰尼单抗

维基百科，自由的百科全书
维基百科中的医学内容仅供参考，并不能视作专业意见。如需获取医疗帮助或意见，请咨询专业人士。详见医学声明。
兰尼单抗
单克隆抗体
种类Fab片段（英语：Fab fragment）
目标血管内皮生长因子A（英语：Vascular endothelial growth factor A）（VEGF-A）
临床资料
商品名（英语：Drug nomenclature）Lucentis, others
生物相似药Ranibizumab-nuna,[1] Ranibizumab-eqrn,[2] Byooviz,[1][3] Cimerli,[2] Ranivisio,[4] Susvimo,[5] Ximluci[6]
AHFS/Drugs.comMonograph
MedlinePlusa607044
核准状况
怀孕分级
给药途径静脉注射
ATC码
法律规范状态
法律规范
药物动力学数据
生物半衰期约9天[10]
识别信息
CAS号347396-82-1  checkY
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
化学信息
化学式C2158H3282N562O681S12
摩尔质量48,379.97 g·mol−1

兰尼单抗（英语：Ranibizumab，也译为雷珠单抗，商品名Lucentis）是一种单克隆抗体片段（FAB），其与贝伐单抗（bevacizumab）是从相同亲本鼠抗体获得。它比母体分子小得多，能更紧密的结合到血管内皮生长因子-A(VEGF-A)。它是一种血管生成抑制剂(angiogenesis inhibitor)，已被批准用于治疗的“湿”型老年黄斑变性。

参考资料

[编辑]
  1. ^ 1.0 1.1 1.2 Byooviz Nuna- ranibizumab injection, solution. DailyMed. 2022-04-27 [2022-08-02]. （原始内容存档于2022-08-03）. 
  2. ^ 2.0 2.1 2.2 Cimerli- ranibizumab-eqrn injection, solution. DailyMed. 2022-10-19 [2023-01-21]. （原始内容存档于2023-01-21）. 
  3. ^ 3.0 3.1 Byooviz EPAR. European Medicines Agency. 2021-06-23 [2021-09-09]. （原始内容存档于2021-09-10）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ 4.0 4.1 Ranivisio EPAR. European Medicines Agency (EMA). 2022-06-20 [2022-10-06]. （原始内容存档于2022-10-06）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ 5.0 5.1 Susvimo- ranibizumab injection, solution. DailyMed. [2021-12-19]. （原始内容存档于2021-12-19）. 
  6. ^ 6.0 6.1 Ximluci EPAR. European Medicines Agency. 2022-09-14 [2023-03-03]. （原始内容存档于2023-03-13）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ 7.0 7.1 AusPAR: Ranibizumab. Therapeutic Goods Administration (TGA). 2014-12-09 [2021-09-20]. （原始内容存档于2021-09-21）. 
  8. ^ 8.0 8.1 https://www.tga.gov.au/resources/auspmd/byooviz [裸露网址]
  9. ^ Summary Basis of Decision - Byooviz. Health Canada. 2022-08-12 [2022-09-29]. （原始内容存档于2022-09-29）. 
  10. ^ 10.0 10.1 Lucentis- ranibizumab injection, solution. DailyMed. [2021-09-20]. （原始内容存档于2021-09-21）. 
  11. ^ Lucentis EPAR. European Medicines Agency. 2018-09-17 [2021-09-09]. （原始内容存档于2021-09-10）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

外部链接

[编辑]
检索自“https://zh.wikipedia.org/w/index.php?title=兰尼单抗&oldid=80155780”